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Abstract
Background: Placebo interventions can have meaningful effects for patients. However, little is known
about the circumstances of their use in clinical practice. We aimed to investigate to what extent and in
which way Swiss primary care providers use placebo interventions. Furthermore we explored their ideas
about the ethical and legal issues involved. Methods: 599 questionnaires were sent to general
practitioners (GPs) and paediatricians in private practice in the Canton of Zurich in Switzerland. To
allow for subgroup analysis GPs in urban, suburban, and rural areas as well as paediatricians were
selected in an even ratio. Results: 233 questionnaires were completed (response rate 47%). 28% of
participants reported that they never used placebo interventions. More participants used impure placebos
therapeutically than pure placebos (57% versus 17%, McNemar's chi2 = 78, p<0.001). There is not one
clear main reason for placebo prescription. Placebo use was communicated to patients mostly as being
"a drug or a therapy" (64%). The most frequently chosen ethical premise was that they "can be used as
long as the physician and the patient work together in partnership" (60% for pure and 75% for impure
placebos, McNemar's chi2 = 12, p<0.001). A considerable number of participants (11-38%) were
indecisive about statements regarding the ethical and legal legitimacy of using placebos. Conclusions:
The data obtained from Swiss primary care providers reflect a broad variety of views about placebo
interventions as well as a widespread uncertainty regarding their legitimacy. Primary care providers
seem to preferentially use impure as compared to pure placebos in their daily practice. An intense debate
is required on appropriate standards regarding the clinical use of placebo interventions among medical
professionals. 
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Abstract  
Background 
Placebo interventions can have meaningful effects for patients. However, little is 
known about the circumstances of their use in clinical practice. We aimed to 
investigate to what extent and in which way Swiss primary care providers use placebo 
interventions. Furthermore we explored their ideas about the ethical and legal issues 
involved. 
Methods 
599 questionnaires were sent to general practitioners (GPs) and paediatricians in 
private practice in the Canton of Zurich in Switzerland. To allow for subgroup 
analysis GPs in urban, suburban, and rural areas as well as paediatricians were 
selected in an even ratio. 
Results 
233 questionnaires were completed (response rate 47%). 28% of participants reported 
that they never used placebo interventions. More participants used impure placebos 
therapeutically than pure placebos (57% versus 17%, McNemar’s χ2 = 78, p<0.001). 
There is not one clear main reason for placebo prescription. Placebo use was 
communicated to patients mostly as being “a drug or a therapy” (64%). The most 
frequently chosen ethical premise was that they “can be used as long as the physician 
and the patient work together in partnership” (60% for pure and 75% for impure 
placebos, McNemar’s χ2 = 12, p<0.001). A considerable number of participants (11-
38%) were indecisive about statements regarding the ethical and legal legitimacy of 
using placebos. 
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Conclusions 
The data obtained from Swiss primary care providers reflect a broad variety of views 
about placebo interventions as well as a widespread uncertainty regarding their 
legitimacy. Primary care providers seem to preferentially use impure as compared to 
pure placebos in their daily practice. An intense debate is required on appropriate 
standards regarding the clinical use of placebo interventions among medical 
professionals. 
 
Background  
Numerous studies demonstrate that placebo interventions can have an influence on 
outcomes and may benefit the patient [1-5]. On the other hand, the evidence that 
placebo interventions can significantly alter clinical outcomes has been questioned, 
and some authors have cautioned against their possible negative effects [6-8]. This 
unsettled dispute about the appropriate role of placebo interventions in clinical 
settings is reflected by the regulatory situation: While the use of placebos in research 
is extensively regulated by national and international guidelines, their use in clinical 
practice often occurs in a legal and ethical gray zone. In this context of normative 
uncertainty the standards that primary care providers develop to guide their own 
practice are of particular interest.  
 
Various definitions of the term “placebo” have been suggested in the literature. We 
usually prefer the term “placebo intervention” because it is not only the concrete 
placebo “vehicle” (i.e. the drug or the procedure) that can influence outcomes but 
rather all context factors including the perceptions and expectations of the patients. 
We define a placebo intervention as an intervention which has no direct 
pharmacological, biochemical or physical mechanism of action according to the 
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current standard of knowledge. It can take the form of a placebo medication or of a 
diagnostic or therapeutic sham procedure.  
We chose to use the distinction between “pure” and “impure” placebos, which is well 
established in the literature [6,8-10]. “Pure placebos” refer to inert substances or 
methods, whereas “impure placebos” include substances or methods which do have a 
known pharmacological or physical activity but which cannot be expected to have any 
direct therapeutic effects for the respective disease and in the chosen dosage.  
We decided to use this distinction although it cannot be applied to all placebo 
interventions in a clear cut way – for instance, diagnostic placebo interventions cannot 
easily be attributed to either category. Our hypothesis was that clinical use and the 
moral reasoning accompanying it would be quite different for both categories so that 
the distinction would help us to gain a more nuanced understanding of the ways 
physicians think about and use placebo interventions. 
In the past twenty years, six surveys have been published that address the attitudes 
and habits of physicians with regard to the use of placebo interventions [10-15]. The 
reported percentage of physicians using placebo interventions in clinical practice 
ranged from 41% to 99% depending on their specialty and, more importantly, the 
context of the survey question. In a Swedish study for instance, the use of antibiotics 
for viral infections was presented to the physicians as a placebo treatment. Thus the 
physicians were focused on impure placebos when they were asked about their 
prescribing habits regarding placebo treatment. This may have led to the high 
percentage of positive responses (99%) [15]. There are publications of surveys which 
do not even mention if a certain definition of the term “placebo” was given to 
participants [13,15]. Defining the term is highly important, however, because many 
 - 5 - 
definitions and conceptions of placebo exist in the literature and therefore different 
conceptions of placebos among survey participants will influence their statements. 
 
Until now no survey has explored whether physicians handle pure and impure 
placebos differently, and the reasons for rejecting or accepting the use of placebo 
interventions have only been touched upon. To our knowledge ours is the first survey 
which systematically studies the potential differences in the use of pure as compared 
with impure placebos. The overall goal of our study was to determine to what extent 
and in which ways Swiss primary care providers utilise placebo interventions. 
Furthermore we explored their ideas about the ethical and legal issues involved. 
Methods 
Participants  
In Switzerland, primary care is mainly provided by general practitioners (GPs) and 
paediatricians, so we chose to send our questionnaire to those two groups. Postal 
addresses were received from a register of the medical association of the Canton of 
Zurich and additionally from the database www.twixtel.ch. A total of 149 addresses 
of paediatricians and 1518 of general practitioners in private practice were available. 
We stratified the addresses of the GPs according to their location and selected 
randomly 150 GPs from urban areas, 150 GPs from suburban areas, and 150 GPs 
from rural areas. The groups were coded by using different colours for the 
questionnaires. The group size was determined by the number of available 
paediatricians. Overall we included 599 primary care providers in our survey. 
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The Research Ethics Committee of the Canton of Zurich stated that the study did not 
require ethical review. 
Questionnaire 
The questionnaire consisted of 14 multi-unit questions on four pages and can be 
downloaded from http://www.ethik.uzh.ch/ibme/team/margritfaessler/Fragebogen.pdf 
in its original German version. For an English version see the Additional file 1. 
Reponses to questions no. 11-14, which focus on participants’ ideas about the mode 
of action of placebo interventions and their relationship to complementary medicine, 
will be reported and discussed elsewhere.  
 
On the top of the questionnaire, we placed our definitions of “placebo intervention”, 
“pure”, and “impure placebos” (Table 1). 
 
Subsequently the questionnaire pointed out that the questions referred only to the use 
of placebo interventions in clinical practice, not to placebos given as controls in 
clinical trials. 
 
In addition to demographic data we focused on the following questions about the use 
of placebo interventions: Which placebo interventions study participants use, whether 
they use placebo interventions at all, for which motives, how often, what they 
communicate to the patient, their attitude towards placebos, and the estimated 
disappointment of patients were they to discover that they had unknowingly received 
a placebo. Responses required the distinction between pure and impure placebos. 
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In three consecutive pilot studies, we pretested our questionnaire with a total of 27 
GPs or paediatricians and revised some wording. The survey was conducted between 
December 2007 and March 2008. The questionnaires were sent out by mail with a 
letter explaining the aim of the survey and the anonymous data processing. Two 
reminders were sent out. Codes on the returning envelopes were used to identify 
participants who did not need a reminder. On return, the envelope was separated from 
the questionnaire for anonymous data processing. 
Statistical analysis 
We processed our data analysis using SPSS version 16. Every item was checked for 
differences caused by the following variables: location area (urban vs. 
suburban vs. rural), paediatricians vs. GPs, gender and age group (<50 vs. ≥50 yrs). In 
order to reduce multiple statistical testing and to obtain only relevant group 
differences, we first checked for group differences amounting to over 15%, and 
applied χ2-testing only to items with group differences above the cut off. 
Differences in ordinal scale variables were assessed by Wilcoxon’s rank sum test (e.g. 
presumed disappointment after knowledge of having received pure as compared to 
impure placebo), while binomial variables were compared with McNemar’s χ2 test 
(e.g. consent to pure vs. impure placebo treatment). Statistical significance level was 
0.05 with a two tailed hypothesis. Values are given as frequencies or mean and SD. 
 
Results  
The final version of the questionnaire was sent out to 599 Swiss primary care 
providers who practise in medical offices. Two of them were returned because their 
addresses were unknown, and 15 respondents declared not to be a GP or paediatrician 
or not to have a private practice. This left a sample of 582. 
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The questionnaires were collected by MG who managed the reminders. For the 
extraction of data the questionnaires were sent from MG to MF as soon as a 
significant amount had been received. 83 of these, mostly filled questionnaires got 
lost by the mailing company and could not be retrieved. To calculate the response rate 
we subtracted the 83 lost questionnaires from the original sample of 582 and set 499 
as 100%, which leads to a 47% response rate for the available 233 completed 
questionnaires.  
 
Demographics 
The characteristics of the respondents are shown in Table 2. The return rate of the 
primary care providers in urban areas was lower than in suburban or rural areas. The 
proportion of female respondents (29%) corresponds to the percentage of women in 
private practice in primary care in the Canton of Zurich (22%) [16]. 
 
Use of placebo interventions  
66 of the 233 (28%) participants reported that they did not make any clinical use 
whatsoever of interventions they considered a placebo. To answer the question 
whether the frequency of therapeutic use of pure and impure placebos was different 
we took the data from participants who answered both question 5 and 6 (“If you use 
pure/impure placebos therapeutically – what do you tell the patient?”), i.e. 203 of the 
233 participants. Significantly more participants used impure placebos (116 of 203) 
than pure placebos (34 of 203) for therapeutic purposes (57% versus 17%, 
McNemar’s χ2 = 78, p<0.001). 93% of those who do use pure placebos used them 
once a month or less, 2% weekly, and 5% daily. 
 - 9 - 
 
Table 3 shows how often different placebo interventions are utilised by the 
participants. In the questionnaire respondents could indicate their view on the 
respective intervention being a placebo intervention or not (last two columns). The 
most frequently mentioned placebo interventions were diagnostic procedures in the 
form of non-essential physical examinations of the patient (89%), followed by 
positive suggestions (81%). Only 7% of the participants had provided sugar pills, 10% 
reported injections with saline solution. Again we did not find any group differences. 
 
Motives for the use of placebo interventions 
Table 4 shows the motives for using placebo interventions among the participants 
using placebos for diagnostic or therapeutic reasons (n = 167). Considering both, the 
group who uses just impure placebos and the group who uses both pure and impure 
placebos together, the most frequently chosen motives were “to gain therapeutic 
advantage through the placebo effect” (69%), “to offer a treatment to patients whose 
complaints and test results are not attributable to a certain disease” (64%), and “to 
conform with the requests of the patient” (63%).  
 
The two least frequently chosen motives overall were “to test whether the pain is 
psychogenic or organic” (21%) and “to avoid drug addiction” (30%). All items were 
chosen more frequently by those who stated to use impure placebos only, with the 
exception of using placebos as a test to distinguish “psychogenic” from “organic 
pain”. The participants had the possibility to note additional motives that guided their 
use of placebo interventions but only 4 of the respondents made use of this option.  
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When looking for interaction with our tested class variables, we found the following 
group differences: Fewer paediatricians than GPs used only impure placebos to treat 
patients with unspecific complaints (23 vs. 40%, p<0.05). Also fewer paediatricians 
than GPs used only impure placebos in difficult patients (13 vs. 33%, p<0.01).  
 
Communication about placebo use 
When using pure or impure placebos, most participants reported telling their patients 
that they received a drug or a therapy (see Table 5). No one reported that he or she 
told the patients that the intervention was a placebo. Relatively few referred to the 
placebo as “a medicine with no specific effect” (11% for pure, 27% for impure 
placebo).  
 
Ethical and legal issues of using placebo interventions 
Study participants were asked if they agreed or disagreed with six statements about 
the use of pure or impure placebos in medical practice (Table 6). Their ”I am 
uncertain” answers ranged from 11 to 38%, with the statement “The use of placebos 
must be rejected in principle because there are legal concerns” provoking most 
uncertainty (38% for the use of pure placebos, 30% for impure placebos). The most 
frequently confirmed statement for both pure and impure placebos was “The use of 
placebos can be used as long as the physician and the patient work together in 
partnership” (60% for pure vs. 75% for impure placebo). For all six questions, there 
was more agreement with the statements regarding the use of impure placebos than of 
pure placebos (Wilcoxon’s rank sum test, z=8.2, p<0.001). 
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As a group difference we found that paediatricians less often than GPs rejected the 
use of pure placebos for its implying the deception of patients (43 vs. 60%, χ2 = 4.7, 
p=0.03). 
 
Presumed patient reaction to being informed about placebo use  
A considerable percentage of participants presumed that many of their patients would 
be disappointed if they came to know that they had been intentionally treated with a 
placebo: This worry was more pronounced regarding the use of pure placebos (55%) 
than in the case of an impure placebo (22%) (p<0.001 by Wilcoxon’s rank sum test) 
(Table 7). Less paediatricians than GPs were worried about their patient’s 
disappointment when a pure placebo had been used (49 vs. 68%, χ2 = 12.4, p<0.01). 
 
Discussion  
Our survey gives a detailed picture of the use of placebo interventions in clinical 
practice and illustrates the attitudes of primary care providers. 72% of the 233 
participants use placebo interventions in certain situations. Overall, far more 
participants make therapeutic use of impure placebos than of pure placebos (57% vs. 
17%). This corresponds to results of a recently published US survey in which 41% of 
the physicians recommended over the counter analgesics as placebo treatment and 2-
3% recommended inert substances within the past year [10]. Within our sample of 
primary care providers we could not detect any differences in the frequency of using 
pure placebos regarding their medical specialty (GP or paediatrician) or the 
localisation of their practice. 
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The most frequently used justification for the use of placebos in medical practice was 
that it can be used as long as the physician and the patient work together in 
partnership: 60% of all participants agreed with this statement with regard to the use 
of pure placebos, and 75% agreed with regard to impure placebos. This emphasis on a 
therapeutic partnership of patients and physicians contrasts, however, with 
participants’ concern about their patients’ disappointment if they found out they were 
intentionally treated with a placebo. Possibly physicians would want to find ways to 
use placebos in a non-deceptive manner that is in accord with a partnership model of 
the physician-patient-relationship, but have not yet found a suitable way of realizing 
this.  
 
The most frequently endorsed argument against the use of placebos concerned the 
deception it implied vis-à-vis the patient: 45% of the participants agreed with this 
argument regarding pure placebos, and 24% regarding impure placebos (p<0.001 for 
pure vs. impure placebos). Other surveys asked somewhat different questions. An 
Israeli survey reported that 5% of participants thought that the use of placebos should 
be categorically prohibited [13]. Surveys from the USA obtained 7 to 12% for this 
item [10,12], and a Danish survey found that placebo interventions were ethically 
unacceptable to 40% of study participants [11]. As the placebo definitions that the 
studies used differ, the possibilities to compare these data are limited.  
 
Why is it useful to distinguish pure from impure placebos? The use of pure or inert 
placebos has met with scepticism by ethicists mainly because it presumably implies 
the deception of the patient, representing an outdated, unduly paternalistic physician-
patient-relationship [17,18]. By contrast, the use of impure or active placebos seems 
 - 13 - 
easier to justify by the (to some extent sophistic) argument that, though not probable, 
these placebos could have some pharmacological or physical activity that has a 
positive effect on the health of the patient but is difficult to verify. One could also 
argue that interventions with impure placebos may have greater placebo effects than 
interventions with pure placebos because the theory and framework of the impure 
placebo intervention can lead to positive expectations or conditioned responses in 
patients. An intervention that is accompanied by positive information in the lay press 
can be expected to work better than a nameless pill without package insert. This 
assumption is in accordance with recent data showing that the use of expensive 
placebo pills reduces pain better than the use of cheaper ones [19]. On the other side it 
should not be neglected that impure placebos can cause harmful side effects, which 
incidentally can be severe, e.g. an allergic reaction to an antibiotic given for a viral 
infection. 
 
In our sample, the use of placebos, be they pure or impure, was usually communicated 
to the patient as a “medication” or “therapy”. It is unknown whether telling patients 
explicitly the nature of placebo treatment compromises placebo effects or not. The 
existing empirical data that deny an influence are weak [20]. It is possible that 
physicians underestimate the effectiveness of placebo interventions in adequately 
informed patients as well as the openness of the latter to try and take advantage of the 
power of the placebo. But this would need to be explored further in studies focusing 
on the patient’s perspective. Still, physicians’ information about medical interventions 
frequently include a grain of interpretation or untruthfulness – be it that the prospect 
of cure is somewhat exaggerated or the likelihood of adverse effects a bit 
downplayed. Determining what degree of such paternalistic, albeit benevolent, 
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manipulation of medical information is appropriate for the individual patient-
physician-relationship is part of a physician’s responsibilities. Often there is an 
implicit mutual agreement and trust that the doctor will make the right choice of 
treatment. 
 
A remarkable finding is the uncertainty among participants as regards the ethical and 
legal status of placebos as well as their effectiveness. 11 to 38% were uncertain how 
to appraise the respective statement presented to them in the questionnaire. Another 
cue revealing the uncertainness of participants is that we found only limited 
agreement on the motives to use placebo interventions. 72% of the participants 
administer placebo interventions to their patients in certain circumstances. There is 
less agreement among those who use placebo interventions for certain motives than 
might be expected. About two-thirds of those who use placebo interventions agreed 
with the three motives “to gain a therapeutic advantage of a placebo effect”, “to offer 
a treatment to patients whose complaints and test results are not attributable to a 
certain disease”, and “to conform with the requests of the patient”. 
 
Other authors found still less consensus regarding the motives or circumstances 
among placebo users. Sherman and Hickner reported that for the respondents who 
used placebos the most common motive was “to calm the patient” and “as 
supplemental treatment” (both 18%) [12]. In the survey of Nitzan and Lichtenberg the 
most frequently reported circumstance for placebo use was “after ‘unjustified’ 
demand for medication” (48%) [13]. Berger found 48% of those who used as well as 
those who usually did not use placebos were likely to use a placebo when they 
suspected factitious pain [14]. Only Hróbjartsson and Norup referred to a more stable 
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consensus: 70% of the general practitioners who used placebo interventions agreed 
about the motive “following the wish of the patient and avoiding a conflict with the 
patient” [11]. All in all, the use of placebo interventions in general practice does not 
seem to follow clear patterns, in particular not from an international, cross-cultural 
perspective. There is not one main clear reason for placebo use. 
 
The reason for the uncertainness of participants may well be due, at least in part, to 
their unfamiliarity with recent or even well-established findings of placebo research, 
e.g. as being reviewed by Price et al. [21]. Another reason may be that there is no 
commonly accepted consensus in the literature on how to use placebo interventions in 
clinical practice. We found neither (Swiss) national nor international policies which 
would help answering the question when and how to use placebo interventions in 
practice, although individual authors have made suggestions to that effect [22]. The 
ubiquitous requirement of informed consent is not fine-grained enough to provide 
much guidance when it comes to the more subtle issues of using placebo 
interventions. For example, there is no guidance on how to explain the mechanism of 
action of a proposed placebo intervention to the patient. Finding the right balance 
between putting the patient off by being too explicit about the placebo nature of the 
intervention and by being so vague as to be almost deceptive is a challenging task that 
might benefit from well-tailored recommendations.  
 
A reassuring finding was that a vast majority of the Swiss primary care providers 
(85%) denied the factual use of placebos to test whether pain is psychogenic or 
organic. There is no evidence in the literature to corroborate the utility or plausibility 
of this test [14,23,24]. Ignoring the slightly different wording of questions in surveys 
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addressing the usefulness of placebos to distinguish symptoms that have a 
psychogenic versus an organic origin, there is a high variability of adherence to this 
misleading theory among physicians: 19% [25], 20% [12], 53% [24], 68% [14] when 
asked for hypothetical use and 4% [12], 18% [11], 19% [13], 48% [14] when asked 
for the factual use. 
 
Some limitations of our study need to be acknowledged. To illuminate many aspects 
of the use of placebo interventions in clinical practice, we developed a rather 
extensive questionnaire which may have cut the response rate. Non-respondents and 
missing data may have led to possible biases. Other surveys about placebo use also 
had response rates under 60% [10,12,23,26], which may well have its reasons in the 
somewhat delicate nature of the topic on the one hand and the high workloads of 
practicing physicians on the other, reducing the readiness to participate in research 
[27]. A formal testing of differences in age and gender for respondents and non-
respondents cannot be presented for our study because we did not collect these data 
from non-respondents. Therefore we can not say whether the low response rate of our 
survey introduced marked bias to our data. However, the age and gender of the 
respondents do fit well with the data of Zurich Medical Association. 
Despite our clearly stated definition of placebo interventions, the answers of the 
participants may have been influenced by different concepts about placebo 
interventions. For example, primary care providers who practice psychotherapy may 
have been confused our definition not explicitly excluding psychotherapy. Placebo 
effects can also be conceived as psychologically mediated effects and therefore it 
seemed inadequate and artificial to us to draw a sharp, explicit line between the 
effects of psychotherapy and placebo effects for the purposes of our definition. Still, 
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had we explicitly included or excluded psychotherapy in our definition some 
participants might have replied differently to the question whether they do or do not 
apply placebo interventions to their patients. 
The reported prevalence of use of pure placebos depended on the subjective criteria 
used to separate pure and impure placebos. For example, participants could consider 
homoeopathic remedies as pure placebos or not. Also, we did not ask for the 
frequency of the use of impure placebos because we assumed that answering this 
question would be very difficult as their use was too prevalent to be reliably 
quantified by an estimation. [15]. 
 
In clinical practice, physicians are often confronted with situations in which either a 
scientifically proven therapy is not known, may have unacceptable side effects, or in 
which the patient’s complaints cannot be interpreted within the framework of a well-
defined diagnosis. In such cases the physician could wait and see whether the 
“unspecific” symptoms may disappear without any intervention. But many patients do 
not get better by mere waiting, and their subjectively perceived illness remains 
considerable. Why not harness “the sometimes powerful beneficial effect of a 
placebo” [28]? The ambivalence and uncertainty of physicians who do not want to fall 
into the trap of arrogant and inappropriate paternalism is quite understandable. There 
may be ways, however, of getting the “power of the placebo” to work without losing 
the patient as a partner. Exploring those possibilities and defining suitable limits to the 
clinical use of placebo interventions seem to be an important next step [29].  
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Conclusions  
The data obtained from Swiss primary care providers reflect a broad variety of views 
about placebo interventions as well as a widespread uncertainty regarding their 
legitimacy. Primary care providers seem to preferentially use impure as compared to 
pure placebos in their daily practice.  
An intense debate is required on appropriate standards on the clinical use of placebo 
interventions among medical professionals that reaches out to the perspective of those 
whose interests and wellbeing are the ultimate goal of all medical interventions: the 
patients.  
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Tables 
Table 1  - Definition of Placebo Intervention, Pure, and Impure Placebos  
 
 
Placebo 
intervention  
 
We define a placebo intervention as a diagnostic or 
therapeutic sham intervention or as an intervention with 
substances or physical methods which have no direct 
pharmacological, biochemical or physical mechanism of 
action according to the current standard of knowledge. The 
term includes a considerable variety of interventions, thus not 
only the administration of lactose tablets or isotonic saline 
solution. 
 
Pure placebos  
Are inert substances or methods such as sugar pills or 
isotonic saline solution. 
 
Impure placebos  
Refer to substances or methods which have a known 
pharmacological or physical activity but which cannot be 
expected to have any direct therapeutic effects for the 
respective disease and in the chosen dosage, e.g. vitamin 
infusions for cancer or peppermint pills for pharyngitis. 
 
Table 2  - Sample characteristics  
 
Category N  Count (percentage) 
or mean ±SD 
Group of physicians 233  
 Paediatricians  67 (29%) 
 GPs in urban areas  41 (18%) 
 GPs in suburban areas  55 (24%) 
 GPs in rural areas  70 (30%) 
 - 24 - 
Gender 227  
 Women  65 (29%) 
 Men  162 (71%) 
Age (years) 228 52 + 9 
Days per week working in private practice 197 4.1 + 1.2 
Patients seen per day 224  
 <15  35 (16%) 
 15-30  150 (67%) 
 >30  39 (17%) 
 
Table 3  - Use of placebo interventions and the question whether the 
participants view the respective intervention as placebo intervention 
 
 N ... I have 
already 
used 
... I have 
not used 
so far 
N … is not a 
placebo 
intervention. 
Positive suggestions 180 146 (81%) 34 (19%) 197 62 (32%) 
Simple ointments and/or bandages for 
contusions without visible skin 
damages 
181 137 (76%) 44 (24%) 197 52 (27%) 
„Sugar pills“ 196 14 (7%) 182 (93%) 197 3 (2%) 
Injections with saline solution 198 20 (10%) 178 (90%) 199 4 (2%) 
Therapies without pharmacological or 
physical efficacy for the patient’s 
conditions (e.g. vitamins or antibiotics 
without approved indication) 
195 119 (61%) 76 (39%) 196 12 (6%) 
Diagnostic practices:      
• non-essential physical 
examinations of the patient 
193 171 (89%) 22 (11%) 200 38 (19%) 
• non-essential technical 
examinations of the patient 
without relevant risks (e.g. 
ultrasound, MRI) 
195 134 (69%) 61 (31%) 197 24 (12%) 
• non-essential technical 
examinations of the patient 
with relevant risks (e.g. 
computed tomography) 
192 59 (31)% 133 (69%) 195 21 (11%) 
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Table 4  - Motives for the use of placebo interventions among the 167 users 
 
 N I use pure 
and impure 
placebos* 
I use only 
impure 
placebos* 
I use no 
placebos at 
all 
To conform with the requests of the patient 159 17 (11%) 83 (52%) 59 (37%) 
To gain a therapeutic advantage through the placebo 
effect 
157 31 (20%) 77 (49%) 49 (31%) 
To still be able to offer a treatment option to a patient 
with an „incurable“ disease 
154 12 (8%) 55 (36%) 87 (56%) 
To offer a treatment in situations in which standard 
treatments may strongly burden patients with side 
effects or are contraindicated 
158 13 (8%) 46 (29%) 99 (63%) 
To offer a treatment to patients whose complaints and 
test results are not attributable to a certain disease 
(unspecific complaints) 
162 24 (15%) 80 (49%) 58 (36%) 
To offer treatment to difficult patients with 
psychological peculiarities, i.e. constant unwarranted 
complaints 
156 19 (12%) 61 (39%) 76 (49%) 
To test whether the pain is psychogenic or organic 154 20 (13%) 12 (8%) 122 (79%) 
To avoid drug addiction 155 12 (8%) 35 (23%) 108 (70%) 
 
*Definitions see Table 1. 
The total percentage may not equal 100 due to rounding. 
 
Table 5  - What participants tell their patients when using placebos for 
therapeutic purposes  
 
 Use of pure placebos 
therapeutically (n=222) 
Use of impure placebos 
therapeutically (n=208) 
User: 35 119* 
I tell them   
… this is a drug / a therapy. 22 (63%) 77 (65%)* 
… this is a placebo. 0 (0%) 0 (0%) 
… this is a medicine with no specific 
effect. 
4 (11%) 32 (27%)* 
I say nothing. 9 (26%) 10 (8%) 
Nonuser:   
I never use placebos for therapeutic 
purposes. 
187  89* 
 
Only one answer allowed, *p<0.001 vs. pure placebo by McNemar’s χ2 test. 
Percentages refer to the number of users.
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Table 6  - Statements regarding the ethical and legal legitimacy of placebo use 
 
  Use   of pure placebos   Use   of  impure placebos  
 N I agree I am un-
certain 
I disagree  N I agree I am un-
certain 
I disagree p value* 
The use of placebos           
• must be rejected in 
principle because it is 
ineffective. 
220 58 
(26%) 
37 
(17%) 
125 
(57%) 
 220 41 
(19%) 
26 
(12%) 
153 
(70%) 
p<0.05 
 
• must be rejected in 
principle because it 
implies deceiving the 
patient. 
223 101 
(45%) 
39 
(17%) 
83 
(37%) 
 221 52 
(24%) 
39 
(18%) 
130 
(59%) 
p<0.001 
• must be rejected in 
principle because of 
legal concerns. 
220 43 
(20%) 
84 
(38%) 
93 
(42%) 
 221 30 
(14%) 
67 
(30%) 
124 
(56%) 
n.s. 
• can be used as long as 
physician and patient 
work together in 
partnership. 
220 132 
(60%) 
35 
(16%) 
53 
(24%) 
 221 166 
(75%) 
25 
(11%) 
30 
(14%) 
p<0.001 
• is acceptable for the 
benefit of the patient 
and for minimizing 
harm to the patient. 
219 120 
(55%) 
43 
(20%) 
56 
(26%) 
 221 158 
(71%) 
24 
(11%) 
39 
(18%) 
p<0.01 
• is for me a traditional 
component of medical 
practice. 
219 37 
(17%) 
25 
(11%) 
157 
(72%) 
 217 91 
(42%) 
26 
(12%) 
100 
(46%) 
p<0.001 
 
Multiple answers allowed. * Significance testing by use of McNemar’s Chisquare 
test, pure vs. impure placebo (“I am uncertain”-answers were excluded from analysis). 
The total percentage may not equal 100 due to rounding. 
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Table 7  - Presumed disappointment of patients if they learned that they had 
been intentionally treated with a pure or impure placebo* 
 
 Use of pure placebo (n=223) Use of impure placebo (n=225) 
Yes, many of my patients 123 (55%) 49 (22%) 
Yes, some of my patients 47 (21%) 53 (24%) 
Mostly no  27 (12%) 103 (46%) 
I do not know.  26 (12%) 20 (9%) 
 
* Counts for pure vs. impure placebo were significantly different, Wilcoxon’s, z=8.7, 
p<0.001. 
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